Pancreatic Cancer: Molecular Targets for Therapy
Pancreatic cancer, synonym pancreas cancer, is a virulent disease with no effective therapy besides surgical resection. The possibility for surgical tumor removal is limited by early metastatic spread of tumor to sites outside the pancreas. The survival for patients with metastatic pancreatic cancer is less than 1 year following diagnosis. Clinicians must translate the available knowledge of the molecular basis of this disease into rationale and effective therapeutic strategies for treatment.
Pancreas cancer is one of the tumors with the highest number of genetic mutations of any solid malignancy. These include oncogenes, tumor suppressor genes, and DNA-stability genes. The stability genes include mismatch repair (MMR) and base excision repair (BER) genes, which control the mutation rate of other genes. A number of genetic alterations have been, and still are being, tested as molecular target for antipancreatic cancer therapy. It is clear that novel molecular targets and...
KeywordsEpidermal Growth Factor Receptor Pancreatic Cancer Focal Adhesion Kinase Pancreatic Cancer Cell Pancreatic Adenocarcinoma
- Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167CrossRefPubMedPubMedCentralGoogle Scholar
- Wallace JA, Locker G, Nattam S et al (2007) Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. Program and abstracts of the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 17–21 Jan Orlando (Abstract 127)Google Scholar